6837-92-9

Basic information

• Product Name: 3-AMINO-N,N-DIETHYL-4-HYDROXY-BENZENESULFONAMIDE
• Synonyms: BenzenesulfonaMide,3-aMino-N,N-diethyl-4-hydroxy-
• CAS NO: 6837-92-9
• Molecular Formula: C₁₀H₁₆N₂O₃S
• Molecular Weight: 244.3106
• Mol File: 6837-92-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 414.7 °C at 760 mmHg
• Flash Point: 204.6 °C
• Appearance: /
• Density: 1.294 g/cm³
• Vapor Pressure: 1.81E-07mmHg at 25°C
• Refractive Index: 1.583
• CAS DataBase Reference: 3-AMINO-N,N-DIETHYL-4-HYDROXY-BENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-N,N-DIETHYL-4-HYDROXY-BENZENESULFONAMIDE(6837-92-9)
• EPA Substance Registry System: 3-AMINO-N,N-DIETHYL-4-HYDROXY-BENZENESULFONAMIDE(6837-92-9)

Safety Data

• Hazardous Substances Data: 6837-92-9(Hazardous Substances Data)

Usage

General Description

3-AMINO-N,N-DIETHYL-4-HYDROXY-BENZENESULFONAMIDE is a chemical compound that belongs to the class of benzene sulfonamides. It is a derivative of benzenesulfonamide and contains an amino group, two ethyl groups and a hydroxy group attached to the benzene ring. 3-AMINO-N,N-DIETHYL-4-HYDROXY-BENZENESULFONAMIDE has various potential applications in pharmaceuticals and agrochemicals due to its specific chemical structure and properties. It may have biological activities and is used as a building block in the synthesis of new drugs or agrochemicals. Additionally, it may be used in research and development processes for the discovery of new therapeutic agents.

InChI:InChI=1/C10H16N2O3S/c1-3-12(4-2)16(14,15)8-5-6-10(13)9(11)7-8/h5-7,13H,3-4,11H2,1-2H3

Upstream product

• 22117-79-9 4-methoxy-3-nitrobenzene-1-sulfonyl chloride 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 
• 97-35-8 1-amino-2-methoxybenzene-5-sulfonic acid diethylamide 

Downstream Products

• 888731-61-1 3-amino-4-(tert-butyldimethylsilyloxy)-N,N-diethylbenzenesulfonamide 

Relevant articles and documents

4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines

Various malignant human diseases show disturbed signaling pathways due to increased activity of proteins within the epigenetic machinery. Recently, various novel inhibitors for epigenetic regulation have been introduced which promise a great therapeutic benefit. Inhibitors for the bromo- and extra-terminal domain (BET) family were of particular interest after inhibitors had shown a strong antiproliferative effect. More recently, the focus has increasingly shifted to bromodomains (BDs) outside the BET family. Based on previously developed inhibitors, we have optimized a small series of 4-acyl pyrroles, which we further analyzed by ITC, X-ray crystallography, selectivity studies, the NCI60 cell-panel, and GI50 determinations for several cancer cell lines. The inhibitors address both, BET and BRD7/9 BDs, with very high affinity and show a strong antiproliferative effect on various cancer cell lines that could not be observed for BD family selective inhibitors. Furthermore, a synergistic effect on breast cancer (MCF-7) and melanoma (SK-MEL-5) was proven.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.